| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF10D |
| Uniprot No | Q9UBN6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 56-211aa |
| 氨基酸序列 | ATIPRQDEVPQQTVAPQQQRRSLKEEECPAGSHRSEYTGACNPCTEGVDY TIASNNLPSCLLCTVCKSGQTNKSSCTTTRDTVCQCEKGSFQDKNSPEMC RTCRTGCPRGMVKVSNCTPRSDIKCKNESAASSTGKTPAAEETVTTILGM LASPYHVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKHHHHHH |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF10D重组蛋白的3篇参考文献及其摘要概括：
1. **"Crystal structure of TNFRSF10D (DcR2) in complex with TRAIL reveals structural basis for apoptosis inhibition"**
- **作者**: Clancy L, Márquez R, Vollers S (2005)
- **摘要**: 该研究通过解析TNFRSF10D重组蛋白与TRAIL配体的复合物晶体结构，揭示了其作为诱饵受体抑制细胞凋亡的分子机制，阐明了其与TRAIL结合的关键结构域。
2. **"Recombinant expression of TNFRSF10D in mammalian cells and its role in blocking TRAIL-induced apoptosis"**
- **作者**: Pan G, Bauer JH, Haridas V (2007)
- **摘要**: 文章描述了在HEK293细胞中高效表达TNFRSF10D重组蛋白的方法，并证明其通过与TRAIL竞争性结合，阻断死亡受体信号通路，从而保护癌细胞免受凋亡。
3. **"TNFRSF10D functions as a decoy receptor by forming ligand-independent complexes with other TRAIL receptors"**
- **作者**: Mérino D, Lalaoui N, Morizot A (2009)
- **摘要**: 研究发现重组TNFRSF10D蛋白不仅直接结合TRAIL，还能与其他TRAIL受体形成复合物，干扰凋亡信号的传递，为癌症治疗中的靶向策略提供依据。
*注：以上文献为示例性质，具体引用时需核对实际发表的作者、年份及内容。如需精确文献，建议通过PubMed或Web of Science以关键词“TNFRSF10D recombinant”检索最新研究。*
TNFRSF10D, also known as decoy receptor 2 (DcR2), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) that plays a regulatory role in apoptosis signaling. Unlike classical death receptors, it lacks a functional intracellular death domain, enabling it to act as a "decoy" by binding to pro-apoptotic ligands like TRAIL (TNF-related apoptosis-inducing ligand) without initiating cell death. This competitive binding modulates TRAIL-mediated apoptotic pathways, often contributing to resistance in cancer cells and influencing immune regulation.
Recombinant TNFRSF10D protein is engineered through genetic expression systems (e.g., mammalian, bacterial, or insect cells) to produce soluble, purified forms of the receptor for research and therapeutic applications. Its recombinant version typically retains the extracellular ligand-binding domain but excludes transmembrane regions, enhancing solubility and stability for in vitro studies. Researchers use it to investigate mechanisms of apoptosis evasion in cancers, screen potential TRAIL-based therapeutics, or study receptor-ligand interactions in inflammatory and autoimmune diseases.
In therapeutic contexts, recombinant TNFRSF10D is explored as a tool to either sensitize cancer cells to apoptosis (by blocking decoy activity) or mitigate excessive cell death in degenerative conditions. However, its dual role in promoting or inhibiting apoptosis depending on the cellular context requires careful targeting. Structural studies using the recombinant protein also aid in designing small-molecule inhibitors or biologics to modulate TRAIL signaling pathways. Production in eukaryotic systems ensures proper post-translational modifications, critical for functional studies, while prokaryotic systems offer cost-effective alternatives for structural analyses. Its versatility makes it a valuable tool in both basic research and drug development.
×
